Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma – an update

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

(2016) Jonathan Corren et al.   CHEST

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels

(2016) Leif Bjermer et al.   CHEST

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

(2016) Claus Bachert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

(2016) Diamant Thaçi et al.   LANCET

Reductions in eosinophil biomarkers by benralizumab in patients with asthma

(2016) Tuyet-Hang Pham et al.   RESPIRATORY MEDICINE

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

(2016) Hector G Ortega et al.   Lancet Respiratory Medicine

Clinical usefulness of mepolizumab in severe eosinophilic asthma

(2016) Francesco Menzella et al.   Therapeutics and Clinical Risk Management

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

(2015) Richard M. Nowak et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

Emerging molecular phenotypes of asthma

(2015) Anuradha Ray et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Mepolizumab-based therapy in asthma

(2015) Garry M. Walsh   Current Opinion in Allergy and Clinical Immunology

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma

(2015) Bart Hilvering et al.   Therapeutic Advances in Respiratory Disease

Self-reported Lifetime Prevalence of Atopic Dermatitis and Co-morbidity with Asthma and Eczema in Adulthood: A Population-based Cross-sectional Survey

(2014) K Bingefors et al.   ACTA DERMATO-VENEREOLOGICA

A New Era of Targeting the Ancient Gatekeepers of the Immune System: Toll-Like Agonists in the Treatment of Allergic Rhinitis and Asthma

(2014) Zahra Aryan et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis

(2014) Pranabashis Haldar et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

(2014) Lisa A. Beck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation

(2014) Roman Skiepko et al.   Postepy Dermatologii i Alergologii

Characterisation of an OCS-dependent severe asthma population treated with mepolizumab

(2014) C M Prazma et al.   THORAX

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

(2014) Mario Castro et al.   Lancet Respiratory Medicine

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge

(2013) H. Scheerens et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

(2013) Michael Noonan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

(2013) Michel Laviolette et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Inhaled allergen bronchoprovocation tests

(2013) Zuzana Diamant et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Inhibiting Interleukin-4 and Interleukin-13 in Difficult-to-Control Asthma

(2013) Michael E. Wechsler   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

(2013) Sally Wenzel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials

(2013) Yao Liu et al.   PLoS One

Mepolizumab for severe eosinophilic asthma

(2013) Douglas S Robinson   Expert Review of Respiratory Medicine

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

(2012) Edward Piper et al.   EUROPEAN RESPIRATORY JOURNAL

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

(2012) Guiquan Jia et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Innate and adaptive immune responses in asthma

(2012) Stephen T Holgate   NATURE MEDICINE

The potential of biologics for the treatment of asthma

(2012) Girolamo Pelaia et al.   NATURE REVIEWS DRUG DISCOVERY

Reslizumab for Poorly Controlled, Eosinophilic Asthma

(2011) Mario Castro et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

(2011) RD May et al.   BRITISH JOURNAL OF PHARMACOLOGY

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

(2011) Aasia Ghazi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Lebrikizumab Treatment in Adults with Asthma

(2011) Jonathan Corren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma

(2010) William W. Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased sputum and bronchial biopsy IL-13 expression in severe asthma

(2008) Shironjit K. Saha et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease

(2008) Gary P Anderson   LANCET

Review: Tissue remodeling and angiogenesis in asthma: the role of the eosinophil

(2008) A.H. Nissim Ben Efraim et al.   Therapeutic Advances in Respiratory Disease